Facilitated By

San Antonio Medical Foundation

Phase Ib Trial of Two Folate Binding Protein (FBP) Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients 2013-0139

Cancer Insight, LLC

Cancer Insight is a Texas-based boutique contract research organization (CRO) dedicated to discovering, developing and testing emerging biotechnologies focused on cancer immunotherapy. Founded by industry pioneer Dr.

Principal Investigator(s)
George Peoples
Funded by
Industry Sponsored
Research Start Date

The goal of this clinical research study is to learn the most effective way to give patients a vaccine in order for the immune system to react against folate binding protein (FBP) and FBP-containing cancers. The E39 and J65 peptide (a piece of a protein) vaccines are designed to cause the immune system to attack certain cancer cells (those with FBP), which may help lower the risk that the cancer will come back.

Drug Discovery